10,000mg Full-Spectrum High-CBD RSO
Scientific Insights into CBD's Potential Anti-Cancer Properties
Experience the power of our 10,000mg Full-Spectrum High-CBD RSO, designed to harness the potential cancer-fighting properties of cannabinoids.
Comprehensive Cannabinoid Profile
Contains a potent blend of cannabinoids, including CBD, CBG, CBN, and CBC, ensuring a full-spectrum experience. Each 1oz bottle offers 120 servings, providing consistent dosing for optimal benefits.
High-Quality Ingredients
Crafted with organic MCT oil, our tincture ensures high absorption and bioavailability. It is free of heavy metals, pesticides, mycotoxins, microbials, and residual solvents, guaranteeing purity and safety.
Serving Recommendations
For best results, we recommend a serving size of .25ml (a quarter dropper) taken 3-4 times a day. This allows for steady cannabinoid levels throughout the day, enhancing overall wellness.
Scientific Insights into CBD's Potential Anti-Cancer Properties
Inhibition of Aggressive Breast Cancer Cells
A 2007 study published in Molecular Cancer Therapeutics revealed that CBD significantly reduces the expression of the Id-1 gene, associated with aggressive breast cancer cells. This suggests potential for CBD in managing breast cancer progression.
Induction of Programmed Cell Death
Research from 2011, also in Molecular Cancer Therapeutics, showed that CBD induces apoptosis (programmed cell death) in breast cancer cells by coordinating the interplay between apoptosis and autophagy. This highlights a potential mechanism through which CBD may combat cancer.
Inhibition of T-Lymphocyte Proliferation
A 2003 study in the European Journal of Pharmacology demonstrated that CBD and other cannabinoids inhibit the proliferation of human and mouse T-lymphocytes, suggesting their role in cancer prevention.
Suppression of Cancer Cell Invasion
Published in 2010, a study in Biochemical Pharmacology found that CBD inhibits cancer cell invasion by upregulating TIMP-1, a tissue inhibitor of matrix metalloproteinases, crucial in preventing cancer metastasis.
Inhibition of Angiogenesis
A 2012 study in the British Journal of Pharmacology showed that CBD inhibits angiogenesis (the formation of new blood vessels) through multiple mechanisms, potentially impeding tumor growth and metastasis.
Review of CBD as an Anticancer Drug
A comprehensive review in the British Journal of Clinical Pharmacology (2013) summarized preclinical and clinical evidence supporting CBD’s potential as an anticancer drug. The review highlighted CBD's ability to induce apoptosis, inhibit cancer cell migration and invasion, and enhance conventional cancer treatments.
Targeting Pancreatic Cancer Cells
Research published in the journal Gut in 2006 found that CBD induces apoptosis in human pancreatic cancer cells via a CB2 receptor-dependent mechanism, suggesting a targeted therapeutic strategy for pancreatic cancer.
Medical Disclaimer
The information provided here is for informational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always consult with a healthcare provider regarding any medical condition or treatment.
FDA Disclaimer
This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. It should not replace conventional cancer treatment and should be used under the guidance of a qualified healthcare professional.
Safety Notice
Individual results may vary, and there is limited scientific evidence supporting its efficacy for cancer treatment. Consult your healthcare provider before starting any new supplement regimen, especially if pregnant, nursing, or taking medications. Use this product at your own risk and discontinue use if adverse reactions occur.
Conclusion
The 10,000mg Full-Spectrum High-CBD RSO offers a potent, clinically formulated option for those seeking the potential benefits of cannabinoids. With its comprehensive cannabinoid profile, high-quality ingredients, and promising scientific support, it stands out as a valuable addition to your wellness regimen.